Is Jardiance Good for Kidneys? Benefits and Risks

Jardiance (empagliflozin) has become one of the most evidence-backed medications for slowing kidney disease progression, and the data is strong enough that it earned an FDA indication specifically for chronic kidney disease in 2025. In the landmark EMPA-KIDNEY trial, empagliflozin reduced the risk of kidney disease progression or cardiovascular death by about 28% compared to placebo, and the benefit held regardless of whether patients had diabetes. That said, the drug comes with real side effects, and understanding a few quirks of how it affects kidney function numbers can save you unnecessary worry.

What the Major Trials Actually Found

Two large randomized trials provide the backbone of the kidney evidence for Jardiance. The first, a kidney-focused analysis of the EMPA-REG OUTCOME trial, enrolled people with type 2 diabetes and established cardiovascular disease. In that study, new or worsening kidney disease occurred in roughly 13% of the empagliflozin group versus about 19% of the placebo group, a 39% relative risk reduction.¹ That benefit was consistent regardless of what other blood-pressure or kidney-related medications patients were already taking.²

The more definitive trial, EMPA-KIDNEY, was designed from the ground up to test whether empagliflozin protects kidneys in a broader population, including people without diabetes. Over a median follow-up of two years, progression of kidney disease or death from cardiovascular causes occurred in about 13% of the empagliflozin group and about 17% of the placebo group. That works out to a hazard ratio of 0.72, meaning empagliflozin cut the relative risk by 28%.³ The results held across different levels of kidney function and whether or not patients had diabetes. In practical terms, this is a substantial reduction. For a drug that patients take once daily as a pill, the consistency and size of the benefit across subgroups is notable.

How It Slows Kidney Decline

Jardiance belongs to the SGLT2 inhibitor class, which works by blocking a transporter in the kidneys that normally reabsorbs glucose back into the bloodstream. By preventing that reabsorption, the drug causes glucose (and some sodium) to leave the body through urine. But the kidney benefits go well beyond blood-sugar control, which is why the drug works even in people without diabetes.

The key mechanism appears to involve reducing pressure inside the kidney’s filtering units. When more sodium reaches a specific sensing region of the kidney tubule (called the macula densa), it triggers a feedback loop that constricts the incoming blood vessel to the glomerulus. The result is lower pressure in the glomerular capillaries, which reduces the strain that drives long-term scarring and function loss. MRI-based imaging studies in people with type 2 diabetes have confirmed that empagliflozin measurably reduces renal blood flow and filtration pressure compared to other diabetes drugs.⁴

A secondary analysis of the EMPA-KIDNEY trial quantified the long-term effect on kidney function decline. After an initial adjustment period, empagliflozin roughly halved the chronic rate of kidney function loss, slowing it from about 2.75 to about 1.37 mL/min per 1.73 m² per year.⁵ That slower rate begins approaching what doctors consider the natural, age-related decline in kidney function. The benefit was present even in patients with little protein leakage in their urine, a subgroup that had been uncertain before EMPA-KIDNEY reported.

The eGFR Dip That Alarms Patients and Doctors

If your doctor starts you on Jardiance and rechecks your kidney labs a few weeks later, your estimated glomerular filtration rate (eGFR) will almost certainly be lower than before. This initial drop, sometimes called the “eGFR dip,” averages around 2 mL/min per 1.73 m² in the first couple of months and represents roughly a 6% decrease.⁵ It can look alarming on paper, especially for someone already anxious about declining kidney function.

The dip is considered a hemodynamic effect: the drug is deliberately reducing pressure inside the glomerulus, so less fluid is being filtered per minute. It is not a sign of kidney damage. Research from the EMPEROR-Reduced heart failure trial confirmed that this mild eGFR decrease after starting empagliflozin was not associated with worsening heart failure, death, or kidney safety events.⁶ Analyses from the EMPA-REG OUTCOME trial similarly showed the dip was largely reversible and reflected the drug’s intended mechanism rather than harm.⁷

The practical takeaway: if you see your eGFR drop modestly in the first month or two on Jardiance, that is expected. Your nephrologist should anticipate it. A large or progressive decline beyond the initial dip is a different story and warrants investigation, but the initial small drop itself is actually a signal that the drug is doing what it’s supposed to do.

Does It Help if You Don’t Have Diabetes?

This is where the evidence has shifted in the last few years. Jardiance was originally approved as a diabetes drug, so many people still associate it exclusively with blood-sugar management. But EMPA-KIDNEY specifically enrolled patients with chronic kidney disease regardless of diabetes status, and the kidney protection was consistent in both groups.³ That finding was a major reason the FDA expanded the drug’s indication to CKD broadly, not just CKD caused by diabetes.⁸

Evidence from the broader SGLT2 inhibitor class reinforces this. Trial data from dapagliflozin, a closely related drug, showed kidney benefits across causes of CKD including hypertensive kidney disease, IgA nephropathy, and focal segmental glomerulosclerosis, with the benefit in non-diabetic kidney disease at least as large as in diabetic kidney disease.⁹ A pilot trial specifically looking at empagliflozin in non-diabetic glomerulonephritis (a category of inflammatory kidney disease) found that it significantly reduced proteinuria progression compared to placebo, though the effect on eGFR decline did not reach statistical significance in that small study.¹⁰

If your nephrologist prescribes Jardiance for kidney disease even though your blood sugar is normal, the recommendation is well-supported. You might feel odd taking what sounds like a “diabetes drug,” but the mechanism of kidney protection operates independently of glucose control.

Reducing Protein in the Urine

Proteinuria and albuminuria (protein leaking through damaged kidney filters into urine) are strong predictors of how fast kidney disease will progress. One of the consistently observed effects of empagliflozin is a reduction in urinary albumin. In the decentralized monitoring trial testing empagliflozin alone, urinary albumin-to-creatinine ratio dropped by about 19% on the drug.¹¹ This effect ties directly into the pressure-lowering mechanism in the glomerulus: less pressure means less protein is forced through the filter.

In the non-diabetic glomerulonephritis trial, empagliflozin reduced proteinuria progression significantly, with a hazard ratio of 0.65, and median proteinuria declined by about 77% over the study period in the empagliflozin group.¹⁰ That is a striking reduction, though it came from a small pilot study and larger trials are needed to confirm the magnitude. Still, across the evidence base, the anti-proteinuria effect is one of the most reliable signals that the drug is meaningfully reducing kidney stress.

Risks and Side Effects Worth Knowing About

Jardiance is generally well tolerated, but it has a specific side-effect profile that comes from its mechanism. Because it dumps extra glucose into the urine, it creates a sugar-rich environment in the urinary tract, and that environment is hospitable to infections.

Urinary tract infections: SGLT2 inhibitor use and the resulting glucosuria (glucose in urine) are both independent positive predictors of bacterial UTIs in people with type 2 diabetes.¹² Most of these infections are routine and respond to standard antibiotics, but the increased frequency is real and worth knowing about, especially for people already prone to UTIs.
Fungal infections: Genital yeast infections are more common with SGLT2 inhibitors, and in rare cases, the fungal risk extends beyond the genital area. There are case reports of serious fungal urinary tract masses in patients taking empagliflozin.¹³ These severe cases are uncommon, but recognizing symptoms early matters.
Euglycemic diabetic ketoacidosis: This is the side effect that catches people most off-guard. Normally, diabetic ketoacidosis happens when blood sugar is very high. SGLT2 inhibitors can trigger a version where the body goes into dangerous ketoacidosis while blood sugar stays deceptively normal or only mildly elevated.¹⁴ The risk rises during acute illness, very low carbohydrate diets, or when insulin doses are reduced. There have been cases occurring within just two to three days of starting the drug when these triggers overlap.¹⁵
Volume depletion: Because the drug increases urine output, dehydration and low blood pressure are possible, particularly in older adults or those already on diuretics. Symptoms include dizziness on standing, lightheadedness, and fatigue.

Euglycemic ketoacidosis, while rare, deserves particular attention because the normal blood sugar reading can delay diagnosis. If you are on Jardiance and develop nausea, vomiting, abdominal pain, or unusual fatigue, especially during an infection or while eating very few carbohydrates, seek medical attention promptly even if your glucose meter reads normal. Your doctor should check blood ketones and acid-base status.

Combining Jardiance with Other Kidney Medications

Most people with CKD are already on an ACE inhibitor or an ARB (angiotensin receptor blocker) for blood pressure and kidney protection. Jardiance works through a different mechanism, so the combination adds a layer of benefit on top of what those drugs provide. The EMPA-REG OUTCOME analysis confirmed that Jardiance’s kidney benefits remained consistent regardless of background medications affecting kidney blood flow.²

The more exciting recent development involves combining Jardiance with finerenone, a newer drug that blocks the mineralocorticoid receptor to fight inflammation and scarring in the kidney. A 2025 trial published in the New England Journal of Medicine tested the combination head-to-head against either drug alone in people with CKD and type 2 diabetes. The combination reduced urinary albumin by about 29% more than finerenone alone and 32% more than empagliflozin alone, with no unexpected safety signals.¹⁶ Symptomatic low blood pressure, acute kidney injury, and high potassium levels leading to stopping the drugs were all uncommon.

The biological rationale for the combination is intuitive: empagliflozin reduces pressure inside the kidney’s filters, while finerenone attacks the inflammation, oxidative stress, and scarring that damage kidney tissue from the other direction.¹⁷ Researchers have suggested that using an ACE inhibitor or ARB, plus an SGLT2 inhibitor like Jardiance, plus finerenone may be able to slow kidney function loss close to the normal age-related rate of about 1 to 1.5 mL/min per year.¹⁸ That would represent a major advance for people facing progressive kidney disease.

Effects on Blood Pressure and Uric Acid

Kidney disease, high blood pressure, and elevated uric acid tend to cluster together, so side benefits in these areas matter. A meta-analysis pooling data from twelve studies and over 7,800 patients with type 2 diabetes found that empagliflozin significantly reduced serum uric acid levels along with both systolic and diastolic blood pressure.¹⁹ Elevated uric acid contributes to gout and has been independently linked to kidney damage, so lowering it is a welcome bonus even if the clinical implications of modest uric-acid reductions are still debated.

An exploratory analysis from the EMPA-KIDNEY trial confirmed that empagliflozin lowered serum uric acid in the CKD population, and the primary kidney outcomes were similar regardless of patients’ baseline uric acid levels.²⁰ In other words, the drug helped kidneys whether uric acid started high or normal, but it also happened to bring uric acid down regardless. The blood-pressure reduction is similarly modest, typically a few mmHg systolic, which on its own would not be dramatic but contributes to a cumulative benefit when you are already managing hypertension with other medications.

Quality of Life and Hospitalizations

One reasonable concern is whether a drug that makes you urinate more, risks UTIs, and requires monitoring actually improves your day-to-day life or just improves numbers on a lab sheet. The EMPA-KIDNEY health-economic analysis addressed this directly. Over two years, patients on empagliflozin gained a small but statistically significant improvement in quality-adjusted life years and spent about one fewer day in the hospital compared to those on placebo. Days in end-stage kidney disease (needing dialysis or transplant) were reduced by about two days over that period.²¹ Two days might not sound transformative, but the trial’s median follow-up was only two years. Over a longer horizon, the benefit compounds: every month you stay off dialysis is a month of dramatically better quality of life.

Self-reported quality-of-life scores (EQ-5D) showed only tiny average differences between the drug and placebo groups, which isn’t surprising. CKD is a slow disease, and at the 18-month mark, most patients in both groups had not yet progressed to the stage where the difference would be felt daily. The real quality-of-life payoff shows up over years, as fewer patients reach kidney failure and the need for dialysis or transplant.

Cost-Effectiveness Across Health Systems

A recurring question for both patients and health systems is whether the cost of Jardiance (which is a brand-name drug without a generic equivalent in most markets) is justified by the downstream savings. Multiple independent economic analyses have concluded it is, and in every case so far, by a wide margin.

A UK analysis projected that empagliflozin added to standard care would add about one extra life year and 0.84 quality-adjusted life years per patient over a 50-year horizon, while actually reducing total per-patient costs by about £6,000, mainly because fewer patients needed kidney replacement therapy.²² A French model found similar results: empagliflozin extended overall survival by about 1.3 years on average and was cost-saving because the drug expense was completely offset by avoided kidney failure events.²³ A Philippine analysis, using local costs and healthcare infrastructure, found even larger projected savings per patient and called the drug economically dominant (better outcomes, lower costs) across both diabetic and non-diabetic CKD populations.²⁴

The pattern across these analyses is consistent: the daily cost of Jardiance is more than paid back by preventing or delaying dialysis, which is extraordinarily expensive everywhere in the world. In the UK model, higher treatment costs were “more than offset by savings in kidney replacement therapy.” For patients worried about out-of-pocket costs, manufacturer assistance programs and the drug’s inclusion in formularies for CKD (separate from its diabetes indication) may help, though access varies by insurer and country. The economic case for payers to cover it is strong enough that coverage has been expanding.

Who Might Not Be a Good Candidate

Despite the broadly positive evidence, Jardiance is not for everyone with kidney disease. People with very advanced CKD (eGFR below about 20 mL/min per 1.73 m²) have limited data, since most trials enrolled patients above that threshold and the drug’s mechanism depends on functioning nephrons to produce its effects. If you are already close to dialysis, the window of benefit narrows considerably.

Anyone with a history of recurrent diabetic ketoacidosis, very low carbohydrate intake, or frequent acute illnesses needs careful monitoring, given the euglycemic ketoacidosis risk. The same applies to people with type 1 diabetes, for whom SGLT2 inhibitors are generally not approved due to higher ketoacidosis rates. People prone to severe or recurrent UTIs should discuss the infection risk frankly with their doctor, as the added glucose in the urine is an ongoing predisposing factor. And because the drug promotes fluid loss, patients on multiple diuretics or those who struggle to stay hydrated (common among older adults) may need dose adjustments or closer follow-up to avoid low blood pressure and dehydration.

Your nephrologist or endocrinologist should also pause the drug before major surgery or during serious acute illness, when ketoacidosis risk is highest and kidney perfusion may already be compromised. Some guidelines call this “sick-day rules” for SGLT2 inhibitors, and it is worth establishing a plan before you ever need it.